Sol-Gel Trialling Benzoyl Peroxide (DER 45 EV, Epsolay) for Rosacea

sol-gelAn intriguing Clinical Trial has been listed on the web site.

The product know only as DER 45 EV Gel (in strengths of 1% and 5%) has been listed in a dose-range trial for the papules and pustules of rosacea.

Clinical Trial NCT00940992, A Dose-Range of DER 45-EV in Treatment of Rosacea (SGT-EBPO1-09)

To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.

DER 45 EV Gel, 1%: Experimental, vs. Placebo Gel applied topically once a day for 12 weeks, vs. DER 45 EV Gel, 5% applied topically once a day for 12 weeks.

It isn’t clear if DER 45 EV is in fact benzoyl peroxide, this is just a guess based on the technologies being promoted by the company sponsoring this trial, Sol-Gel. The company’s technology is to use silica based microcapsules (cutely named Cool Pearls) that will allow a continual release of the active ingredient. Their Anti-Acne kit consists of a cleanser, toner, lotion and also spot treatment.

Update: we now know that this product will be marketed as Epsolay.

Sol-Gel Anti-Acne Clinical Study Shows Significantly Improved Efficacy and Safety

The results demonstrate that the company’s two strength Anti-Acne kits achieved pronounced efficacy and markedly improved tolerability.

“In the Sol-Gel kits, the proprietary silica microcapsules encase and continuously release the benzoyl peroxide, enabling a significant increase in efficacy and tolerance in comparison to products containing free benzoyl peroxide,”

The marketing material for Sol-Gel Technologies gives the following description of the process behind creating their products – “Silicate materials are made by forming interconnections among colloidal nano-sized particles (the sol) under increasing viscosity, until a rigid mass is formed with about half the density of glass (the gel). Sol-Gel precisely engineers the process to fine-tune the size, structure and properties of the materials formed. The resulting drug delivery properties range from completely non-leachable to a selectively porous barrier that allows controlled release of active ingredients after the product is applied to the skin.”

The trial is listed to start in January 2010 so perhaps we will be able to find out more information before then.

This is a potentially interesting development, especially if this means that a harsh treatments such as benzoyl peroxide is tolerable by and beneficial to rosacea sufferers.

As many rosacea sufferers will know from their own experiences, many acne treatments are just too harsh for their sensitive rosacea skin.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.